MORRISTOWN, N.J., March 27, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that it expects to resume distribution of the 20 mg dosage strength of Zohydro® ER (hydrocodone bitartrate) with BeadTek® on March...Read More
TORONTO, March 21, 2018 (GLOBE NEWSWIRE) -- Platinex Inc. (CSE:PTX) (the "Company" or "Platinex") announces that the Company’s investee, Intergalactic Foods, LLC (“IGF”), has received a processing license from the Oregon Liquor Control Commission...Read More
TORONTO, March 13, 2018 (GLOBE NEWSWIRE) -- Platinex Inc. (CSE:PTX) (the "Company" or “Platinex") announced today that it has changed its auditor from Mahendra CA Professional Corporation ("Former Auditor") to UHY McGovern Hurley LLP ("Successor Audit...Read More
TORONTO, March 13, 2018 (GLOBE NEWSWIRE) -- Platinex Inc. (CSE:PTX) announces execution of a shares-for-debt settlement transaction of cumulative overdue advance royalty payments in which Platinex will issue 292,307 common shares at a price of $0.13 per share to Skead Holdings Ltd., in connect...Read More
MORRISTOWN, N.J., March 08, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today financial results for the three and twelve months ended December 31, 2017. Fourth Quarter 2017 Financial Highlights Fourth quarter net re...Read More
MORRISTOWN, N.J., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that the Company will report financial results for the fourth quarter and fiscal year ended December 31, 2017, after the market close on Thur...Read More
MORRISTOWN, N.J., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced the launch of an authorized generic version of Treximet® (sumatriptan/naproxen sodium) in the U.S. by the Company’s subsidiary, M...Read More
Director John R. Leone Named as the Company’s Lead Independent DirectorAngus Smith Promoted to Senior Vice President, Chief Business Officer and Principal Financial Officer MORRISTOWN, N.J., Feb. 06, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty...Read More
MORRISTOWN, N.J., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that it has entered into a settlement agreement with Actavis Laboratories FL (“Actavis”) resolving patent litigation related to...Read More
Anticipated Cost Savings of $7-$8 Million MORRISTOWN, N.J., Jan. 05, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that, due to the impending loss of exclusivity of TREXIMET® (sumatriptan and naproxen sodium...Read More
MORRISTOWN, N.J., Nov.16, 2017(GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced the election of two new directors to its Board, John R. Leone and Douglas J. Swirsky at P...Read More
Vancouver, British Columbia--(Newsfile Corp. - November 10, 2017) - Platinex Inc. (CSE: PTX) has entered into a Letter of Intent to acquire an interest in an edible brand in the State of Oregon, that holds the rights to a brand known in the Southern and Western Oregon regions. The Letter of Intent a...Read More
MORRISTOWN, N.J., Nov.07, 2017(GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) ("Pernix" or the "Company"), a specialty pharmaceutical company, announced today financial results for the third quarter ended September 30, 2017. Third Quarter 2017 Financial Highlights:Third quart...Read More
MORRISTOWN, N.J., Nov.06, 2017(GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) ("Pernix" or the "Company"), a specialty pharmaceutical company, today announced the sale of a non-core product, Cedax (R) (ceftibuten capsules and ceftibuten for oral suspension), a third-generatio...Read More
MORRISTOWN, N.J., Oct.26, 2017(GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) ("Pernix" or the "Company"), a specialty pharmaceutical company, announced today that the Company will report financial results for the third quarter ended September 30, 2017, after the market close...Read More
MORRISTOWN, N.J., Oct.17, 2017(GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) ("Pernix" or the "Company"), a specialty pharmaceutical company, today announced that Graham Miao, Ph.D., President and Chief Financial Officer (CFO), will leave the Company at the end of the year i...Read More
MORRISTOWN, N.J., July27, 2017(GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) ("Pernix" or the "Company"), a specialty pharmaceutical company, today announced financial results for the three and six months ended June 30, 2017. Second Quarter 2017 Financial Highlights:Second q...Read More
TORONTO, ONTARIO--(Marketwired - July 25, 2017) - Platinex Inc. (CSE:PTX)(CSE:PTX.CN)(CNSX:PTX) ("Platinex" or the "Company") has engaged FMI Capital Advisory Inc. ("FMI") as financial advisor to assist in its efforts to grow, finance, secure projects, and in connection with a tr...Read More
TORONTO, ONTARIO--(Marketwired - July 21, 2017) - Platinex Inc. (CSE:PTX)(CSE:PTX.CN)(CNSX:PTX) (the "Company" or "Platinex") announces that the forty five day period set out in a Letter of Intent with Cannabee Products, Inc announced on June 7, 2017 has expired without concludin...Read More
MORRISTOWN, N.J., July20, 2017(GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) ("Pernix" or the "Company"), a specialty pharmaceutical company, today announced certain preliminary unaudited financial results for the second quarter ended June 30, 2017. Second Quarter 2017 Preli...Read More